Clinical trial

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With…

NCT00062894 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00062894
Title Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
Official title A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 1/Phase 2
Study type Interventional
Conditions Non-Hodgkin's Lymphoma
Intervention type Drug
Interventions Iodine I 131 Tositumomab
Enrollment 12
Start date Apr 1, 2003
Completion Apr 1, 2007
First posted Jun 19, 2003
Last update posted Sep 17, 2007
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies